Xiangyu Gao # 1, Ke Ji # 2, Yongning Jia # 1, Fei Shan # 1, Ye Chen # 3, Nong Xu # 4, Ziyu Jia # 2, Tianshu Liu 5, Nong Yang 6, Haijun Zhong 7, Changzheng Li 8, Zengqing Guo 9, Qingxia Fan 10, Xiaoyan Lin 11, Yan Zhang 2, Hui Ren 2, Hongxia Yang 2, Zhifang Yao 12, Wei Liu 12, Zhongmin Maxwell Wang 12, Baiyong Li 12, Michelle Xia 12, Lin Shen 13, Ziyu Li 14, Jiafu Ji 15 ； Cadonilimab with chemotherapy in unresectable HER2-negative gastric or 2 gastroesophageal junction adenocarcinoma (COMPASSION-04): a phase 1b/2 trial,Nature Medicine.,

Xiangyu Gao#, Nong Xu#, Ziyu Li#, Lin Shen#, Ke Ji#, Zhong Zheng#, Dan Liu, Hanmei Lou Li Bai, Tianshu Liu, Yunxia Li, Yuzhi Li, Qingxia Fan, Mei Feng, Haijun Zhong, Yi Huang, Ge Lou, Jing Wang, Xiaoyan Lin, Ye Chen, Ruifang An, Changzheng Li, Qi Zhou, Xin Huang, Zengqing Guo, Shubin Wang, Guiling Li, Junwei Fei, Lijing Zhu, Hong Zhu, Xiumin Li, Fenghu Li, Sihai Liao, Qinghua Min, Lei Tang, Fei Shan, Jifang Gong, Yunong Gao, Jun Zhou, Zhihao Lu, Xiaofan Li, Jianjie Li, Hui Ren, Xiaohong Liu, Hongxia Yang, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Xiaohua Wu*, Jiafu Ji*；Safety and antitumour activity of Cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (AK104-201): a multicentre, open-label, phase 1b/2 trial.,Lancet Oncology,2023 Oct; 24(10):1134-1146.

Xiao-Huan Tang#, Xiao-Long Wu#, Xue-Jun Gan, Yi-Ding Wang, Fang-Zhou Jia, Yi-Xue Wang, Yan Zhang, Xiang-Yu Gao*, Zi-Yu Li*； Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer,International Journal of Molecular Sciences,2023 Jul 29;24(15):12192

Qian Guo#, Chuanke Zhao#, Xiangyu Gao#, Lixin Ding, Pei Wang, Ya’nan Ren, Xingguo Hou, Yuan Yao, Cheng Zhang*, Xianteng Yang*, Zhi Yang* and Hua Zhu*；One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals,Molecular Pharmaceutics,2023 May 22

Xiaohuan Tang, Mengyuan Li, Xiaolong Wu, Ting Guo, Li Zhang, Lei Tang, Fangzhou Jia,Ying Hu, Yan Zhang, Xiaofang Xing, Fei Shan, Xiangyu Gao* and Ziyu Li* Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer,Oncoimmunology,

Xiaohuan Tang 1, Ting Guo 1, Xiaolong Wu 1, Xuejun Gan 1, Yiding Wang 1, Fangzhou Jia 2, Yan Zhang 1,Xiaofang Xing 1,*, Xiangyu Gao 1,* and Ziyu Li 1,*； Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer,Biomolecules,(2022) 12(10):1459

Xiaohuan Tang1, Xiaolong Wu1, Ting Guo1, Fangzhou Jia 2, Ying Hu2, Xiaofang Xing1,Xiangyu Gao1* and Ziyu Li 1；Focal Adhesion-Related Signatures Predict the Treatment Efficacy of Chemotherapy and Prognosis in Patients with Gastric Cancer.,Front Oncol,(2022) 12:808817

XiaoHuan Tang1,2, Ting Guo1, XiangYu Gao1,2, Xiao?Long Wu1,2, XiaoFang Xing1*, JiaFu Ji1,2* and ZiYu Li1,2*；Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications.,Molecular Cancer,(2021) 20(1):99.

Zhonghua Ma#, Xiangyu Gao#, You Shuai#, Xiaofang Xing*, Jiafu Ji*；The m6A epitranscriptome opens a new charter in immune system logic,Epigenetics,

Ziyu Li#, Xiaolong Wu#, Xiangyu Gao#, Jiafu Ji*；Development and validation of a novel staging system integrating the number and location of lymph nodes for gastric adenocarcinoma,British Journal of Cancer,

Ziyu Li#, Xiaolong Wu#, Xiangyu Gao#, Jiafu Ji* Development and validation of an artificial neural network prognostic model after gastrectomy for gastric carcinoma: An international multicenter cohort study,Cancer Medicine,

Ziyu Li#, Xiangyu Gao#, Xinxin Peng#, Mei-Ju May Chen#, Zhe Li#, Han Liang*, Jiafu Ji* Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy.,Science Advances,

Zhonghua Ma#, You Shuai#, Xiangyu Gao#, Xianzi Wen*, Jiafu Ji* Circular RNAs in the tumour microenvironment,Molecular Cancer,

2023首届北京大学”临床科学家”培养计划, 临床科学家, 第1完成人, 北京大学, 2023.1

北京市医院管理中心青年人才培养“青苗”计划, 青年人才培养“青苗”计划, 第1完成人, 北京大学肿瘤医院, 2020.1

一种肿瘤标志物及其应用, 发明专利, 第3完成人, 北京肿瘤医院（北京大学肿瘤医院）, 中国, 2022.8

一种胃癌标志物及其应用, 发明专利, 第3完成人, 北京肿瘤医院（北京大学肿瘤医院）, 中国, 2022.5

血浆外泌体生物标志物在胃癌新辅助化疗敏感人群筛查或疗效预测中的应用, 发明专利, 第5完成人, 北京肿瘤医院（北京大学肿瘤医院）, 中国, 2023.5

C10orf71功能缺失突变介导糖酵解途径调控胃癌新辅助化疗耐药的机制研究, 课题负责人, 2023.1.1～2026.12.31, 国家自然科学基金面上项目

基于影像-病理-多组学的MSI-H/dMMR胃癌双特异性单抗免疫治疗疗效智能预测研究, 子课题负责人, 2023.1.1～2026.12.31, 国家自然科学基金重大研究计划-集成项目

胃癌新辅助免疫治疗前后免疫微环境时空演进机制, 课题负责人, 2023.1.1～2024.12.31, 北京大学临床科学家培养计划

外泌体分子标志物甄选胃癌新辅助治疗潜在获益人群研究, 课题负责人, 2023.1.1～2023.12.31, 北京大学临床肿瘤学院

miR-1307-3p作为ceRNA诱导胃癌化疗耐药的分子机制研究, 课题负责人, 2022.1.1～2023.12.31, 北京大学临床肿瘤学院

胃癌新辅助治疗前后免疫微环境时空演进机制, 课题负责人, 2021.6.1～2023.5.31, 2020 希思科-恒瑞肿瘤研究基金项目

新辅助免疫治疗微卫星不稳定亚型胃癌免疫微环境时空演化规律及其染色质开放性机制研究, 课题负责人, 2022.1.1～2022.12.31, 北京大学临床+X青年专项

基于单细胞组学新辅助化疗前后肿瘤微环境演化, 课题负责人, 2021.1.1～2021.12.31, 北京市医院管理中心青年人才培养“青苗”计划

胃癌新辅助治疗前后免疫微环境时空演进机制, 课题负责人, 2020.1.1～2021.11.30, 北京市示范性研究型病房建设项目

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2025	肿瘤学	硕士	科学学位	胃癌免疫微环境时空演进机制及重塑规律	全国统考